Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment: 2010-2024

  • Ani Pharmaceuticals' Asset Writedowns and Impairment was N/A to $7.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $10.3 million, marking a year-over-year change of. This contributed to the annual value of $7.6 million for FY2024, which is N/A change from last year.
  • Per Ani Pharmaceuticals' latest filing, its Asset Writedowns and Impairment stood at $7.6 million for Q4 2024, which was up 760,100.00% from -$1,000 recorded in Q3 2022.
  • Ani Pharmaceuticals' 5-year Asset Writedowns and Impairment high stood at $7.6 million for Q4 2024, and its period low was -$1,000 during Q3 2022.
  • Its 2-year average for Asset Writedowns and Impairment is $3.8 million, with a median of $3.8 million in 2022.
  • Data for Ani Pharmaceuticals' Asset Writedowns and Impairment shows a peak YoY surged of 596.19% (in 2021) over the last 5 years.
  • Ani Pharmaceuticals' Asset Writedowns and Impairment (Quarterly) stood at $341,000 in 2020, then spiked by 596.19% to $2.4 million in 2021, then reached -$1,000 in 2022, then reached $7.6 million in 2024.
  • Its Asset Writedowns and Impairment was $7.6 million in Q4 2024, compared to -$1,000 in Q3 2022 and $2.4 million in Q4 2021.